99169-46-7

Basic information

• Product Name: 2-isobutylisonicotinamide
• Synonyms: 2-isobutylisonicotinamide;EOS-61997
• CAS NO: 99169-46-7
• Molecular Formula: C10H14N2O
• Molecular Weight: 178.23096
• EINECS: -0
• Mol File: 99169-46-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-isobutylisonicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-isobutylisonicotinamide(99169-46-7)
• EPA Substance Registry System: 2-isobutylisonicotinamide(99169-46-7)

Safety Data

• Hazardous Substances Data: 99169-46-7(Hazardous Substances Data)

Upstream product

• 100369-85-5 ethyl 2-isobutylisonicotinate 
• 100141-62-6 2-chloro-6-isobutyl-isonicotinic acid ethyl ester 
• 100-48-1 pyridine-4-carbonitrile 
• 99067-83-1 2-(2-methylpropyl)-4-cyanopyridine 
• 29840-73-1 2-bromopyridine-4-carboxamide 

Relevant articles and documents

Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis

Ethionamide is a key antibiotic prodrug of the second-line chemotherapy regimen to treat tuberculosis. It targets the biosynthesis of mycolic acids thanks to a mycobacterial bioactivation carried out by the Baeyer-Villiger monooxygenase EthA, under the control of a transcriptional repressor called EthR. Recently, the drug-like molecule SMARt-420, which triggers a new transcriptional regulator called EthR2, allowed the derepression a cryptic alternative bioactivation pathway of ethionamide. In order to study the bioactivation of a collection of thioisonicotinamides through the two bioactivation pathways, we developed a new two-step chemical pathway that led to the efficient synthesis of eighteen ethionamide analogues. Measurements of the antimycobacterial activity of these derivatives, used alone and in combination with boosters BDM41906 or SMARt-420, suggest that the two different bioactivation pathways proceed via the same mechanism, which implies the formation of similar metabolites. In addition, an electrochemical study of the aliphatic thioisonicotinamide analogues was undertaken to see whether their oxidation potential correlates with their antitubercular activity measured in the presence or in the absence of the two boosters.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists. Compounds of the invention may also find use in treating cancer. Presented herein are novel compounds bearing a perhaloalkylsulfonamide moiety. Such compounds, in addition to being highly effective SREBP inhibitors, are also unexpectedly highly bioavailable in vivo. Heteroaromatic compounds bearing sulfonamide groups are prone to several ionic states, based on the inherent pKa values.